1. Home
  2. HWBK vs BDSX Comparison

HWBK vs BDSX Comparison

Compare HWBK & BDSX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

HWBK

Hawthorn Bancshares Inc.

HOLD

Current Price

$32.57

Market Cap

231.4M

Sector

Finance

ML Signal

HOLD

Logo Biodesix Inc.

BDSX

Biodesix Inc.

HOLD

Current Price

$6.67

Market Cap

62.5M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
HWBK
BDSX
Founded
1865
2005
Country
United States
United States
Employees
N/A
N/A
Industry
Major Banks
Precision Instruments
Sector
Finance
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
231.4M
62.5M
IPO Year
N/A
2020

Fundamental Metrics

Financial Performance
Metric
HWBK
BDSX
Price
$32.57
$6.67
Analyst Decision
Strong Buy
Analyst Count
0
5
Target Price
N/A
$32.50
AVG Volume (30 Days)
10.9K
66.8K
Earning Date
01-21-2026
11-03-2025
Dividend Yield
2.48%
N/A
EPS Growth
259.86
N/A
EPS
3.19
N/A
Revenue
$77,904,000.00
$80,173,000.00
Revenue This Year
N/A
$20.75
Revenue Next Year
N/A
$25.05
P/E Ratio
$10.10
N/A
Revenue Growth
45.83
22.29
52 Week Low
$25.21
$3.44
52 Week High
$36.49
$31.20

Technical Indicators

Market Signals
Indicator
HWBK
BDSX
Relative Strength Index (RSI) 42.54 42.44
Support Level $32.07 $6.56
Resistance Level $33.05 $7.03
Average True Range (ATR) 0.96 0.57
MACD -0.44 -0.13
Stochastic Oscillator 11.84 25.24

Price Performance

Historical Comparison
HWBK
BDSX

About HWBK Hawthorn Bancshares Inc.

Hawthorn Bancshares Inc is a financial holding company and along with its subsidiary, it conducts general banking and trust business, offering its customers checking and savings accounts, internet banking, certificates of deposit, trust services, brokerage services, and safety deposit boxes. The company also offers a range of lending services, including commercial and industrial loans, single payment personal loans, installment loans, and commercial and residential real estate loans.

About BDSX Biodesix Inc.

Biodesix Inc is a diagnostic solutions company with a focus in lung disease. The Company has a single operating segment focused on providing diagnostic testing services to customers. It provides biopharmaceutical companies with services that include diagnostic research, clinical trial testing, and the discovery, development, and commercialization of companion diagnostics. The revenue is derived from two sources, providing diagnostic testing services associated with blood-based lung and Covid tests; and providing biopharmaceutical companies with services generally provided outside the clinical setting and governed by individual contracts with third parties as well as development and commercialization of companion diagnostics.

Share on Social Networks: